Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 19 days ago Drug news

FDA accepts filing of Adcetris + chemo to treat advanced classical Hodgkin lymphoma.- Seattle Genetics.

Seattle Genetics, Inc. announced that the FDA has accepted for filing a supplemental Biologics License Application (BLA) for Adcetris (brentuximab...

Added 1 month ago Drug news

Frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma

Phase III ECHELON-1 data presented at ASH for Adcetris + chemo to treat untreated advanced classical Hodgkin lymphoma.

Added 2 months ago Drug news

Innovative study presented at the American College of Rheumatology compare biosimilars with their reference medicines

Sandoz announces data from four clinical studies comparing proposed biosimilar adalimumab & biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan.

Search all news articles for Hodgkin's disease

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more


Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma

The objective of this guideline is to provide healthcare professionals with guidance on the investigation and management of patients with...

Added 2 years ago

Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UK

This guideline is intended to be of use to haematologists and intensivists practising in the UK, and outlines some of...

Added 2 years ago

Hodgkin's Lymphoma: ESMO Clinical Practice Guidelines

The 2014 update elaborates on two histologically distinguished entities: classical Hodgkin's lymphoma that accounts about 95% of cases and nodular lymphocyte-predominant Hodgkin's lymphoma...

Added 1 year ago

Search all guidelines for Hodgkin's disease

Journal articles

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.

Added 1 month ago

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action.

Added 7 months ago

Search all journal articles for Hodgkin's disease

Clinical trials

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD...

Added 2 months ago

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as...

Added 9 years ago

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy...

Added 9 months ago

Search all clinical trials for Hodgkin's disease
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.